Icagen

Xmark Sends Letters to Icagen's Board of Directors: Questions Company's Leadership as Well as Motives Behind Adoption of Poison Pill

...rk Funds are significant shareholders in Icagen, Inc. (the " Company " or " icagen "). On at least three occasions, we have requested permission to obser...In such cases, we have always acted to protect our interests. Regrettably, icagen has become such a case. By way of background specific to Icagen, the X...

Drug Company Halts Late-Stage Trial of Sickle-Cell Disease Drug

... Drug manufacturer icagen announced that it has ended its Phase III clinical trial of its sickle-cell treatment senicapoc, citing lack of effectiveness//, the Raleigh News & Ob...

Icagen in Medical Technology

Icagen Terminates Phase III ASSERT Study

...ptions for the development of senicapoc. About icagen Icagen, Inc. is a biopharmaceutical company base...ated scientific and drug development capabilities, icagen has identified multiple drug candidates that modul...ompany is conducting preclinical studies. icagen is also conducting ongoing drug discovery programs...

Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

...nk posted on the investor relations section of the icagen website at www.icagen.com. The webcast will also b...east two weeks following the presentation. About icagen Icagen, Inc. is a biopharmaceutical company base...ated scientific and drug development capabilities, icagen has identified multiple drug candidates that modul...

Icagen in Biological Technology

Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign

RIDGEFIELD, Conn., April 1 /PRNewswire/ -- On April 1, 2009, Xmark Opportunity Partners, LLC, the sole member of the investment manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the following letter to the Board of Directors of Icagen, Inc. (Nasdaq: ICGN ). ...